Baicalein inhibits the pharmacokinetics of simvastatin in rats via regulating the activity of CYP3A4

Figures & data

Figure 1. The plasma concentration-time curve of 40 mg/kg simvastatin in the presence (test group) or absence (control group) of 20 mg/kg baicalein.

Table 1. The pharmacokinetic parameters of 40 mg/kg simvastatin in rats with (test group) or without (control group) the pre-treatment of 20 mg/kg baicalein.

	Control group	Test group
AUC(0–t) (μg/L×h)	653.05 ± 160.10	2018.58 ± 483.11
t1/2 (h)	4.89 ± 1.04	10.18 ± 2.43
Tmax (h)	2.83 ± 0.75	1.83 ± 0.62
Cmax (μg/L)	85.63 ± 13.28	173.69 ± 35.49
Clz/F (L/h/kg)	63.80 ± 23.39	17.39 ± 5.36

Figure 2. Effect of baicalein on the activity of CYP3A4. The activity of CYP3A4 was evaluated by detecting the concentration of specific metabolites in the presence of 0, 2.5, 5, 10, 25, 50, and 100 μM baicalein.